{"id":"NCT00450658","sponsor":"Amgen","briefTitle":"Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers","officialTitle":"A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-03","primaryCompletion":"2008-09","completion":"2008-10","firstPosted":"2007-03-22","resultsPosted":"2011-06-21","lastUpdate":"2024-12-16"},"enrollment":627,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Peptic Ulcer"],"interventions":[{"type":"DRUG","name":"HZT-501","otherNames":[]},{"type":"DRUG","name":"Ibuprofen","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate whether HZT-501 is effective in reducing the rate of development of ibuprofen-associated ulcers in patients who require long-term daily use of ibuprofen.","primaryOutcome":{"measure":"Number of Subjects Who Develop Endoscopically-diagnosed Upper Gastrointestinal Ulcers Confirmed by Endoscopy.","timeFrame":"24 weeks","effectByArm":[{"arm":"HZT-501","deltaMin":40,"sd":null},{"arm":"Ibuprofen","deltaMin":38,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0018"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":10},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26165391"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":415},"commonTop":["dyspepsia","nausea","upper respiratory tract infection","diarrhea","constipation"]}}